Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × anlotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 42 Small Cell Lung Carcinoma 19 Sarcoma 15 Breast Neoplasms 13 Lung Neoplasms 9 Stomach Neoplasms 8 Neoplasms 8 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Hepatocellular 7 Thyroid Neoplasms 6 Ovarian Neoplasms 6 Triple Negative Breast Neoplasms 5 Pancreatic Neoplasms 5 NSCLC 5 Uterine Cervical Neoplasms 4 Nasopharyngeal Carcinoma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma 4 Neoplasm Metastasis 3 Glioma 3 Endometrial Neoplasms 3 Cholangiocarcinoma 3 Carcinoma, Renal Cell 3 Brain Neoplasms 3 Biliary Tract Neoplasms 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Platinum-resistant Ovarian Cancer 2

Interventions

Temozolomide 373 Radiotherapy 187 Bevacizumab 143 Radiation 73 Magnetic Resonance Spectroscopy 67 Lomustine 45 pembrolizumab 38 Surgical Procedures, Operative 37 Irinotecan 37 Carmustine 37 Nivolumab 27 Carboplatin 25 Specimen Handling 24 Radiosurgery 23 Erlotinib Hydrochloride 23 Radiotherapy, Intensity-Modulated 20 Chemotherapy, Adjuvant 20 Aminolevulinic Acid 19 Cyclophosphamide 18 Drug Therapy 17 sargramostim 16 O(6)-benzylguanine 14 Radiotherapy, Conformal 13 Granulocyte-Macrophage Colony-Stimulating Factor 13 Blood Specimen Collection 13 Everolimus 12 temsirolimus 11 Vorinostat 11 Sunitinib 11 Imatinib Mesylate 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04004975 2019-07-02

Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib

Shandong Cancer Hospital and Institute

Phase 1/2 Unknown

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡